CAMBRIDGE, Mass.--(BUSINESS WIRE)--GenePeeks, Inc., a computational genomics company focused on transforming genetic disease risk analysis, today announced a new partnership with Bioiatriki, a primary healthcare services provider with extensive diagnostic capabilities at its twenty-nine diagnostic centers across Greece and Cyprus.
This new distribution agreement represents the latest step towards GenePeeks’ goal of making its next-generation preconception test available to families around the world. Unlike traditional carrier screening, GenePeeks Preconception Screen identifies the combined parental risk of passing on more than 1,100 serious genetic diseases.
“GenePeeks is delighted to add Bioiatriki to our growing list of global partners,” said Anne Morriss, Co-founder and Chief Executive Officer of GenePeeks. “As one of the largest providers of laboratory services in the region, with a reputation for unrelenting clinical excellence, Bioiatriki is an ideal partner for our organization. With this agreement, we are continuing our international expansion and increasing access to our advanced analytics platform.”
Dr. Evangelos Spanos, President and Chief Executive Officer of Bioiatriki stated, “We welcome the addition of the GenePeeks Preconception Screen to our growing portfolio of innovative medical services. The ability to provide a comprehensive approach to preconception screening, which also reduces the population biases of traditional carrier screening, continues our commitment to bringing advanced technologies to our network of clinicians and the patients they serve.”
About GenePeeks’ Screening Technology
GenePeeks’ preconception screening technology uniquely integrates simulated DNA information from two genetic participants to predict the future genome of a child prior to conception. For every mutation in these hypothetical genomes, the company’s proprietary variant interpretation pipeline computes a Variant Gene Dysfunction (VGD) score that predicts gene function and associated disease risk. This automated, CLIA certified process allows GenePeeks to uncover disease risk with increased sensitivity and go beyond the limits of the clinical data to evaluate variants that may remain uncharacterized by other genetic tests.
GenePeeks is a computational genomics company focused on transforming how genetic disease risk is identified. GenePeeks’ patented technology simulates the complex genetic interactions that occur naturally in human reproduction and the inheritance of disease risk. The company’s next-generation approach addresses the primary challenges of genomic analysis today, including the pervasiveness of rare and novel disease-causing mutations, the high incidence of variants of uncertain significance (VUS), and the population bias embedded in clinical literature and databases. GenePeeks offers its physician-ordered services through its CLIA certified clinical laboratory.
GenePeeks is privately held, with corporate offices in Cambridge, Mass. For more information, visit www.genepeeks.com
GenePeeks’ next-generation screening technology is available today. For more information about becoming a partner, please contact email@example.com
Bioiatriki was founded in 1981 by Dr. Evangelos Spanos and soon gained the trust of the medical community by providing high-quality, comprehensive medical services to all patients. Today, Bioiatriki has established itself as a leading primary healthcare services provider in Greece and Cyprus, with twenty-nine autonomous diagnostic centers that receive over two million patient visits per year. In addition to diagnostic laboratories, Bioiatriki also owns three clinics located in Athens, Piraeus, and Thessaloniki and employs over 2,000 employees, including 400 specialized physicians. Bioiatriki’s mission is to work tirelessly to further improve and upgrade healthcare services across Greece and Cyprus. For more information, visit www.bioiatriki.gr